MERLIN Biotech is an mRNA platform start-up innovative biotechnology spinout from the Baruch S. Blumberg Institute. MERLIN leverages proven mRNA technology to develop novel therapeutics and vaccines that address important unmet medical needs like adult and pediatric cancer, chronic hepatitis B, and Lyme disease.  

MERLIN’s leadership and boards include a former Moderna Senior VP, a Nobel Laureate, and global experts in mRNA development, oncology immune-modulators, chronic hepatitis B, and preventive vaccines for Lyme disease.  

MERLIN Biotech seeks to apply proven mRNA technology for the development of novel therapeutics and vaccines to address important unmet medical needs.